课题基金 / 基金详情

Correlates of protection against SIV/SHIV challenge

Correlates of protection against SIV/SHIV challenge
抵御 SIV/SHIV 挑战的相关性
批准号:
7645935
负责人:
Hildegund C. J. Ertl
金额:
$283.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2011-08-31

项目摘要

项目成果

Hildegund C. J. Ertl的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
_________________________________________________________________________________________ It is the primary objective of this program to elucidate correlates of immune-mediated protection against HIV-1 infection using pre-clinical animal models. To this end, Project 1 will determine humoral and cell-mediated immune responses to an attenuated SIV, termed SIVGY that induces protective immunity to subsequent challenge with a heterologous pathogenic SIV. Project 3 will determine immune responses elicited by different prime-boost vaccine regimens using combinations of DNA vaccines, E1-deleted adenovirus (Ad) vectors and poxvirus vectors. Project 2 will use passive immunization with neutralizing antibodies to determine baseline parameters of antibody-mediated protection with the long-term to develop vaccines that induce B and T cells. Project 3 will assess the role of vaccine-induced mucosal T cells in limiting the spread of SIV. It is the secondary objective of this program to determine if vaccine-induced immune responses including those induced by Ad vectors can be detrimental and if further modifications of E1-deleted Ad vectors can improve both their safety and immunogenicity/efficacy. To this end, Project 3 will test the hypothesis that CD4+ T cell responses induced by viral vector vaccines against the transgene product or components of the vector facilitate disease progression upon SIV infection of nonhuman primates. Project 1 will attempt to improve the efficacy and safety profile of Ad vector vaccines by generating and testing 2nd generation E1-deleted Ad vectors that will have an additional deletion of E2a to reduce synthesis of the highly immunogenic structural antigens of Ad vectors. The application is subdivided into the following 3 Projects and 2 Cores. Project 1 (H. Ertl): Vaccine-Induced Correlates of Protection Project 2 (R. Ruprecht): Neutralizing Antibody Coverage for CTL Vaccines Project 3 (G. Silvestri): Mucosal T Cell Responses and Protection from Simian AIDS Core A (H. Ertl): Administrative Core Core B (X. Zhou): Vector Core
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV-1 Vaccine Based on Chimp Serotypes of Adenovirus
  • 批准号:
    7789929
  • 项目类别:
  • 资助金额:
    $20.0万
  • 财政年份:
    2009
  • 负责人:
    Hildegund C. J. Ertl
  • 依托单位:
GENE REPLACEMENT THERAPY AND THE IMMUNE SYSTEM
  • 批准号:
    7885360
  • 项目类别:
  • 资助金额:
    $35.49万
  • 财政年份:
    2009
  • 负责人:
    Hildegund C. J. Ertl
  • 依托单位:
Correlates of protection against SIV/SHIV challenge
  • 批准号:
    7924012
  • 项目类别:
  • 资助金额:
    $274.92万
  • 财政年份:
    2009
  • 负责人:
    Hildegund C. J. Ertl
  • 依托单位:
Administrative Core
  • 批准号:
    7694087
  • 项目类别:
  • 资助金额:
    $13.66万
  • 财政年份:
    2008
  • 负责人:
    Hildegund C. J. Ertl
  • 依托单位:
国内基金
海外基金
加密/签名的密钥泄露保护机制研究
  • 批准号:
    60970111
  • 项目类别:
    面上项目
  • 资助金额:
    33.0万元
  • 批准年份:
    2009
  • 负责人:
    陈克非
  • 依托单位: